206 Optimising Sucralfate Prescribing in Upper GastroIntestinal and Bariatric Patients: A Cost-Effective Switch from Suspension to Tablets

Abstract Aim To improve the cost-effectiveness of sucralfate prescribing in UGI/bariatric patients by encouraging the use of tablet formulations over high-cost suspensions, while maintaining clinical appropriateness and patient safety. Method A retrospective audit was conducted in two cycles. The first included 39 patients prescribed sucralfate suspension (Jan 2022–Dec 2024), and the second included 9 bariatric/Upper GI patients prescribed sucralfate tablets (Jan–June 2025). Data were collected on indication, prior PPI/H2RA use, surgical history, treatment duration, MDT involvement and cost. Statistical comparison was made using Mann–Whitney’s test. Results In both cycles, the majority had prior PPI therapy (92% vs. 89%). Indications were similar (bile gastritis or post-surgical ulcers). MDT discussions occurred in 67% of patients, with 33% considered for further surgery. Tablet prescriptions were used exclusively in the second cycle. Mean treatment duration was comparable (74 vs. 70.7 days). The cost for 9 patients on tablets over 6 months was £3,015, compared to a projected £17,250 for suspension over the same period—an 82.5% cost reduction. Conclusions Switching from sucralfate suspension to tablets in bariatric patients resulted in substantial cost savings without compromising clinical appropriateness or MDT engagement. This intervention supports sustainable prescribing and may be generalisable to other high-cost liquid formulations.